TTK HEALTHCARE LTD.-$ Q1 FY27 Results

TTK Healthcare's standalone revenue came in at ₹257.56 Cr, up 13.7% YoY and 18.2% QoQ, with PAT of ₹21.28 Cr, up 63.7% YoY but down 2.2% QoQ. Basic EPS was ₹15.06, against ₹9.20 a year ago and ₹15.40 last quarter. The company carries no subsidiaries, so standalone is the sole basis for these results.

The headline YoY PAT jump is materially inflated by a one-off: Note 3 discloses the company invoiced ₹7.02 Cr (₹701.85 lakh) of USAID export orders against Protective Devices inventory that had been fully written off in FY25, meaning near the entire amount drops to pre-tax profit. Stripping this out at the quarter's 26.3% effective tax rate, adjusted PAT growth is ~24% YoY versus 13.7% revenue growth — still profit outgrowing revenue, but far short of the 64% reported figure. Net margin improved to 7.76% from 5.32% YoY (though it compressed from 9.23% in Q4FY26), while operating margin rose to 5.72% from a depressed 1.18% a year ago. The Protective Devices segment was the swing factor, moving to a ₹6.13 Cr segment profit from a ₹5.44 Cr loss in Q1FY26 — the single largest driver of the YoY improvement, substantially aided by the one-off order. Animal Welfare segment profit, by contrast, fell to ₹1.15 Cr from ₹2.34 Cr YoY despite segment revenue growth, partially offsetting the Protective Devices strength.

The stock went into the print at ₹1,123.4, up 23% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.

No formal Street consensus estimates or management guidance for this quarter were found on record or via web search — TTK Healthcare is thinly covered as a small-cap, so vsStreet and vsGuidance are marked unknown/none rather than assumed. The management press release furnished only the standard Regulation 30 board-outcome disclosure with no forward commentary to grade against. Separately, on July 23, 2026 the company signed a definitive agreement to sell its EVA and Good Home brands (Consumer Products segment) to Wipro Enterprises for ₹256 Cr against a net book value of just ₹0.70 Cr; the deal is expected to close by September 30, 2026 and its gain is not reflected in this quarter's numbers.